ESC 365 - Benefits of SGLT2-1/2 Inhibition on Heart Failure, Ischemic, and Kidney Endpoints

Back

ESC Premium Access

Benefits of SGLT2-1/2 Inhibition on Heart Failure, Ischemic, and Kidney Endpoints

Session: Latest Science in CV Prevention

Topic: Diabetes and the Heart

Speaker: Professor D. Bhatt (New York City, US)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Professor Deepak Bhatt

Mount Sinai Hospital, New York City (United States of America)

36 presentations

4 followers

6 more presentations in this session

Nationwide trends in stroke and atrial fibrillation in patients with incident type 2 diabetes

Speaker: Doctor C. Gyldenkerne (Aarhus, DK)

Access

Slides

Video

CRISP-CT: Incorporating FAI-Score In Clinical Decision Making

Speaker: Professor C. Antoniades (Oxford, GB)

Access

Slides

Video

Opiates and its effects on cardiovascular outcomes

Speaker: Doctor S. Liew (Melbourne, AU)

Access

Slides

Video

E3 Trial: The 52-Week Results

Speaker: Doctor K. Filion (Montreal, CA)

Access

Slides

Video

Long term effects of the Randomized Evaluation of Secondary Prevention by Outpatient Nurse Specialists-2 trial (RESPONSE-2)

Speaker: Doctor H. Jorstad (Amsterdam, NL)

Access

Slides

Video

Access the full session

Latest Science in CV Prevention

Speakers: Professor D. Bhatt, Doctor C. Gyldenkerne, Professor C. Antoniades, Doctor S. Liew, Doctor K. Filion...

Access

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

27 August 2021

ESC Premium Access

The long non-coding RNA Heat4 is upregulated in heart failure and decreases the immune response of non-classical monocytes

27 August 2021

ESC Premium Access

Additive prognostic value of cardiac biomarkers in patients with chronic obstructive pulmonary disease and heart failure

27 August 2021

Benefits of SGLT2-1/2 Inhibition on Heart Failure, Ischemic, and Kidney Endpoints

About the speaker

Professor Deepak Bhatt

6 more presentations in this session

Nationwide trends in stroke and atrial fibrillation in patients with incident type 2 diabetes

CRISP-CT: Incorporating FAI-Score In Clinical Decision Making

Opiates and its effects on cardiovascular outcomes

E3 Trial: The 52-Week Results

Long term effects of the Randomized Evaluation of Secondary Prevention by Outpatient Nurse Specialists-2 trial (RESPONSE-2)

Access the full session

Latest Science in CV Prevention

About the event

ESC Congress 2021 - The Digital Experience

Related content

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

The long non-coding RNA Heat4 is upregulated in heart failure and decreases the immune response of non-classical monocytes

Additive prognostic value of cardiac biomarkers in patients with chronic obstructive pulmonary disease and heart failure

ESC 365 is supported by